Toxicity of MRI and CT contrast agents
- PMID:19368492
- DOI: 10.1517/17425250902873796
Toxicity of MRI and CT contrast agents
Abstract
Anatomical and physiological imaging using CT and MRI are playing a critical role in patients' diagnosis, disease characterization and treatment planning. CT- and MRI-based protocols increasingly require an injection of iodinated CT and gadolinium (Gd)-based MRI contrast media. Although routinely used in clinical practice, iodinated and to a less extent Gd-based contrast media possess side effects: life-threatening contrast-induced nephropathy (CIN) is associated with CT and nephrogenic systemic fibrosis (NSF) with MRI contrast agents. CIN is defined as an acute decline in renal functions (serum creatinine increase > 0.5 mg/dl) after administration of iodinated contrast media. Patients with moderate-to-severe chronic kidney disease are considered the highest risk group for development of CIN. CIN is more common with ionic high-osmolar contrast CT media. NSF is a rare condition characterized by the formation of connective tissue in the skin and systemically in the lung, liver, heart and kidney. Patients with end stage kidney disease, acute kidney injury and stage 4-5 chronic kidney disease are at a high risk for NSF. The nonionic linear Gd-chelates are associated with the highest risk of NSF. This review summarizes the incidence, symptoms, safety profile of various CT and MRI contrast agents based on their physiochemical properties.
Similar articles
- Imaging patients with chronic kidney disease: CIN or NSF?Thomsen HS.Thomsen HS.Radiol Med. 2007 Aug;112(5):621-5. doi: 10.1007/s11547-007-0168-y. Epub 2007 Jul 24.Radiol Med. 2007.PMID:17653629English, Italian.
- Nephrogenic systemic fibrosis and management of high-risk patients.Altun E, Semelka RC, Cakit C.Altun E, et al.Acad Radiol. 2009 Jul;16(7):897-905. doi: 10.1016/j.acra.2009.01.001. Epub 2009 Apr 17.Acad Radiol. 2009.PMID:19375360Review.
- Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?Neuwelt EA, Hamilton BE, Varallyay CG, Rooney WR, Edelman RD, Jacobs PM, Watnick SG.Neuwelt EA, et al.Kidney Int. 2009 Mar;75(5):465-74. doi: 10.1038/ki.2008.496. Epub 2008 Oct 8.Kidney Int. 2009.PMID:18843256Free PMC article.Review.
- [Kidney and iodinated and gadolinium-based contrast agents].Clément O, Faye N, Fournier L, Siauve N, Frija G.Clément O, et al.J Radiol. 2011 Apr;92(4):291-8. doi: 10.1016/j.jradio.2011.02.017. Epub 2011 Apr 3.J Radiol. 2011.PMID:21549885Review.French.
- Toxicity of contrast media: an update.ten Dam MA, Wetzels JF.ten Dam MA, et al.Neth J Med. 2008 Nov;66(10):416-22.Neth J Med. 2008.PMID:19011267Review.
Cited by
- Multimodality imaging probes: design and challenges.Louie A.Louie A.Chem Rev. 2010 May 12;110(5):3146-95. doi: 10.1021/cr9003538.Chem Rev. 2010.PMID:20225900Free PMC article.Review.No abstract available.
- Molecular Imaging and Contrast Agent Database (MICAD): evolution and progress.Chopra A, Shan L, Eckelman WC, Leung K, Latterner M, Bryant SH, Menkens A.Chopra A, et al.Mol Imaging Biol. 2012 Feb;14(1):4-13. doi: 10.1007/s11307-011-0521-3.Mol Imaging Biol. 2012.PMID:21989943Free PMC article.Review.
- T1-mapping characterization of two tumor types.Payne MM, Mali I, Shrestha TB, Basel MT, Timmerman S, Pyle M, Sebek J, Prakash P, Bossmann SH.Payne MM, et al.Biophys Rep (N Y). 2024 Jun 12;4(2):100157. doi: 10.1016/j.bpr.2024.100157. Epub 2024 May 23.Biophys Rep (N Y). 2024.PMID:38795740Free PMC article.
- Synthesis and Preclinical Characterization of a Cationic Iodinated Imaging Contrast Agent (CA4+) and Its Use for Quantitative Computed Tomography of Ex Vivo Human Hip Cartilage.Stewart RC, Patwa AN, Lusic H, Freedman JD, Wathier M, Snyder BD, Guermazi A, Grinstaff MW.Stewart RC, et al.J Med Chem. 2017 Jul 13;60(13):5543-5555. doi: 10.1021/acs.jmedchem.7b00234. Epub 2017 Jun 27.J Med Chem. 2017.PMID:28616978Free PMC article.
- Iron-doped calcium phytate nanoparticles as a bio-responsive contrast agent in1H/31P magnetic resonance imaging.Ziółkowska N, Vít M, Laga R, Jirák D.Ziółkowska N, et al.Sci Rep. 2022 Feb 8;12(1):2118. doi: 10.1038/s41598-022-06125-7.Sci Rep. 2022.PMID:35136162Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical